AU2010339723B2 - Early marker of proteinuria in patients treated with an anti-VEGF treatment - Google Patents

Early marker of proteinuria in patients treated with an anti-VEGF treatment Download PDF

Info

Publication number
AU2010339723B2
AU2010339723B2 AU2010339723A AU2010339723A AU2010339723B2 AU 2010339723 B2 AU2010339723 B2 AU 2010339723B2 AU 2010339723 A AU2010339723 A AU 2010339723A AU 2010339723 A AU2010339723 A AU 2010339723A AU 2010339723 B2 AU2010339723 B2 AU 2010339723B2
Authority
AU
Australia
Prior art keywords
podocytes
human
therapy
proteinuria
urinary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010339723A
Other languages
English (en)
Other versions
AU2010339723A1 (en
Inventor
Vesna D. Garovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Clinic in Florida
Original Assignee
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research, Mayo Clinic in Florida filed Critical Mayo Foundation for Medical Education and Research
Publication of AU2010339723A1 publication Critical patent/AU2010339723A1/en
Application granted granted Critical
Publication of AU2010339723B2 publication Critical patent/AU2010339723B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2010339723A 2009-12-21 2010-12-21 Early marker of proteinuria in patients treated with an anti-VEGF treatment Ceased AU2010339723B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28851409P 2009-12-21 2009-12-21
US61/288,514 2009-12-21
PCT/US2010/061543 WO2011084791A2 (en) 2009-12-21 2010-12-21 Early marker of proteinuria in patients treated with an anti-vegf treatment

Publications (2)

Publication Number Publication Date
AU2010339723A1 AU2010339723A1 (en) 2012-08-09
AU2010339723B2 true AU2010339723B2 (en) 2014-11-06

Family

ID=44306097

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010339723A Ceased AU2010339723B2 (en) 2009-12-21 2010-12-21 Early marker of proteinuria in patients treated with an anti-VEGF treatment

Country Status (8)

Country Link
US (4) US20130034861A1 (enExample)
EP (1) EP2517014B1 (enExample)
JP (1) JP5753541B2 (enExample)
AU (1) AU2010339723B2 (enExample)
BR (1) BR112012017767A2 (enExample)
CA (1) CA2785273A1 (enExample)
ES (1) ES2530866T3 (enExample)
WO (1) WO2011084791A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090104649A1 (en) 2007-06-11 2009-04-23 Garovic Vesna D Markers for preeclampsia
ES2530866T3 (es) 2009-12-21 2015-03-06 Mayo Foundation Marcador temprano de proteinuria en pacientes tratados con un tratamiento anti-VEGF
EP2940471B1 (en) * 2012-12-26 2019-09-18 Hara, Masanori Method for detecting podocytes in urine
WO2021055089A1 (en) * 2019-09-20 2021-03-25 The University Of North Carolina At Chapel Hill Methods of identifying risk of bevacizumab-induced proteinuria and hypertension

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9306053D0 (en) 1993-03-24 1993-05-12 Nycomed Pharma As Method and assay
US6969591B2 (en) 2000-10-27 2005-11-29 Masanori Hara Method for diagnosing nephropathy
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
EP1481249A1 (en) 2002-03-07 2004-12-01 Cambridge University Technical Services Limited Scd fingerprints
US20030198959A1 (en) * 2002-03-28 2003-10-23 Kurnit David M. Methods and compositions for analysis of urine samples in the diagnosis and treatment of kidney diseases
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
JP2007532913A (ja) 2004-04-16 2007-11-15 ユニバーシティー オブ マサチューセッツ 細胞内病原体の検出法および定量化法
AU2005277350A1 (en) * 2004-08-17 2006-03-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Method of pre-selecting patients for anti-vegf, anti-hif-1 or anti-thioredoxin therapy
US7790463B2 (en) 2006-02-02 2010-09-07 Yale University Methods of determining whether a pregnant woman is at risk of developing preeclampsia
US7820159B2 (en) * 2006-10-31 2010-10-26 Instiute of Virology of the Slovak Academy of Sciences MN/CA IX and EGFR pathway inhibition
CA2672560A1 (en) * 2006-12-15 2008-06-26 Ruprecht-Karls-Universitaet Heidelberg Methods for treating podocyte-related disorders
KR101722033B1 (ko) 2007-05-21 2017-03-31 웨이크 포리스트 유니버시티 헬스 사이언시즈 소변으로부터의 전구 세포 및 이를 사용하는 방법
US20090104649A1 (en) 2007-06-11 2009-04-23 Garovic Vesna D Markers for preeclampsia
US20090068683A1 (en) 2007-06-11 2009-03-12 Mayo Foundation For Medical Education And Research Markers for preeclampsia
CA2703154A1 (en) * 2007-10-25 2009-04-30 Philogene, Inc. Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (vegf)
WO2010065968A1 (en) 2008-12-05 2010-06-10 Myriad Genetics, Inc. Cancer detection markers
EP2442106B1 (en) 2009-06-10 2015-08-19 Masanori Hara Method for test on diabetic nephropathy
ES2530866T3 (es) 2009-12-21 2015-03-06 Mayo Foundation Marcador temprano de proteinuria en pacientes tratados con un tratamiento anti-VEGF
WO2011143499A1 (en) 2010-05-12 2011-11-17 Tengion, Inc. Bioactive renal cells
CA2875137C (en) 2012-06-01 2021-06-08 Mayo Foundation For Medical Education And Research High-throughput early detection and point-of-care early detection of pregnant women susceptible to developing preeclampsia
CN104736724A (zh) 2012-10-05 2015-06-24 日立化成株式会社 尿液外泌小体mRNA和使用其检测糖尿病型肾病的方法
WO2015080838A1 (en) 2013-11-27 2015-06-04 Mayo Foundation For Medical Education And Research Detecting podocyte injury in diabetic nephropathy and glomerulonephritis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Garovic, V. D. et al. (2007) American Journal of Obstetrics & Gynecology, Vol. 196, pages 320.e1 to 320.e7 *
Izzedine, H. et al. (2010) European Journal of Cancer 46: 439-448 *

Also Published As

Publication number Publication date
WO2011084791A3 (en) 2011-11-24
US20180002416A1 (en) 2018-01-04
ES2530866T3 (es) 2015-03-06
EP2517014A4 (en) 2013-07-17
US10336822B2 (en) 2019-07-02
CA2785273A1 (en) 2011-07-14
JP2013515268A (ja) 2013-05-02
WO2011084791A2 (en) 2011-07-14
US20130296397A1 (en) 2013-11-07
US20130034861A1 (en) 2013-02-07
AU2010339723A1 (en) 2012-08-09
BR112012017767A2 (pt) 2019-09-24
US9213038B2 (en) 2015-12-15
US20160060333A1 (en) 2016-03-03
US9765137B2 (en) 2017-09-19
JP5753541B2 (ja) 2015-07-22
EP2517014B1 (en) 2014-11-19
EP2517014A2 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
Vermeire et al. How, when, and for whom should we perform therapeutic drug monitoring?
Suwannalai et al. Avidity maturation of anti–citrullinated protein antibodies in rheumatoid arthritis
Van Schouwenburg et al. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients
Nurbhai et al. Oral anti-tumour necrosis factor domain antibody V565 provides high intestinal concentrations, and reduces markers of inflammation in ulcerative colitis patients
US10336822B2 (en) Early marker of proteinuria in patients treated with an anti-VEGF treatment
Aubert et al. Risk of antibody-mediated rejection in kidney transplant recipients with anti-HLA-C donor-specific antibodies
AU2018378971A1 (en) Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase l1 (UCH-L1)
Lee et al. Comparison of infliximab drug measurement across three commercially available ELISA kits
Bertin et al. Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: a comparison of three commercially available ELISA kits
US20100015643A1 (en) Method of quantitative determination of antigen protein and quantitative determination kit therefor
Yokode et al. Anti-integrin αvβ6 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitis
Miyazaki et al. Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study
Jilani et al. Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay
Leleu et al. Novel M-component based biomarkers in Waldenström's macroglobulinemia
Nguyen et al. Relationship between serum ustekinumab trough concentration and clinical and biochemical disease activity: a real-world study in adult patients with Crohn’s disease
Helmers et al. Sera from anti–Jo‐1–positive patients with polymyositis and interstitial lung disease induce expression of intercellular adhesion molecule 1 in human lung endothelial cells
Sznol et al. Key issues in the management of gastrointestinal immune-related adverse events associated with ipilimumab administration
Rosas et al. Practical aspects of biological throught levels and antidrug antibodies in rheumatoid arthritis and spondyloarthritis
CA2859221C (en) Lamin a/c and prelamins as indicators of frailty and vulnerability or resiliency to adverse health outcomes
Fichtner et al. Risk of cellular or antibody-mediated rejection in pediatric kidney transplant recipients with BK polyomavirus replication—an international CERTAIN registry study
Caicedo et al. Establishing clinically meaningful ranges of metal hypersensitivity in orthopaedic patients using COVID-19 vaccine-induced adaptive immune responses from fully vaccinated adults
Gill et al. Inflammatory Bowel Disease: Diagnosis and Management
Kenanidis et al. The serum levels of Receptor Activator of Nuclear Factor-κB Ligand, bone-specific alkaline phosphatase, osteocalcin and osteoprotegerin do not correlate with the radiographically assessed severity of idiopathic hip and knee osteoarthritis
Mendolaro et al. Standard therapeutic approach and new therapies
Muñoz-Villafranca et al. Infliximab and Adalimumab Monitoring versus Clinical Control during Maintenance Therapy in Randomized Patients with Inflammatory Bowel Disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired